0001213900-24-029354.txt : 20240402 0001213900-24-029354.hdr.sgml : 20240402 20240402163031 ACCESSION NUMBER: 0001213900-24-029354 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240402 DATE AS OF CHANGE: 20240402 EFFECTIVENESS DATE: 20240402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TFF Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001733413 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 824344737 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-509405 FILM NUMBER: 24814758 BUSINESS ADDRESS: STREET 1: 2600 VIA FORTUNA, SUITE 360 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: 737-802-1973 MAIL ADDRESS: STREET 1: 2600 VIA FORTUNA, SUITE 360 CITY: AUSTIN STATE: TX ZIP: 78746 D 1 primary_doc.xml X0708 D LIVE 0001733413 TFF Pharmaceuticals, Inc. 1751 RIVER RUN SUITE 400 FORT WORTH TX TEXAS 76107 817-438-6168 DELAWARE None None Corporation true ROBERT S. MILLS, JR. 1751 RIVER RUN SUITE 400 FORT WORTH TX TEXAS 76107 Director BRANDI ROBERTS 1751 RIVER RUN SUITE 400 FORT WORTH TX TEXAS 76107 Director KIRK COLEMAN 1751 RIVER RUN SUITE 400 FORT WORTH TX TEXAS 76107 Executive Officer CATHERINE LEE 1751 RIVER RUN SUITE 400 FORT WORTH TX TEXAS 76107 Director ZAMANEH MIKHAK 1751 RIVER RUN SUITE 400 FORT WORTH TX TEXAS 76107 Executive Officer STEPHEN ROCAMBOLI 1751 RIVER RUN SUITE 400 FORT WORTH TX TEXAS 76107 Director HARLAN WEISMAN 1751 RIVER RUN SUITE 400 FORT WORTH TX TEXAS 76107 Executive Officer Director THOMAS KING 1751 RIVER RUN SUITE 400 FORT WORTH TX TEXAS 76107 Director MICHAEL PATANE 1751 RIVER RUN SUITE 400 FORT WORTH TX TEXAS 76107 Director Pharmaceuticals Decline to Disclose 06b false 2024-03-22 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE 3RD FLOOR NEW YORK NY NEW YORK 10022 IL ILLINOIS NY NEW YORK false 1180000 0 1180000 Concurrent with a registered offering, warrants were issued to purchase up to an aggregate of 147,500 shares of common stock at $8.00 per share. Gross proceeds will come from the exercise of the warrants to the extent such warrants are exercised for cash. false 2 82600 0 Represents the 7% cash fee paid to the placement agent in the concurrent registered direct offering referenced in item 13. 0 false TFF Pharmaceuticals, Inc. /s/ Kirk Coleman KIRK COLEMAN CHIEF FINANCIAL OFFICER 2024-04-02